Ebrantil, 5 mg/ml 10 ml 5 pcs

Ebrantil refers to drugs which block post-synaptic alpha-1-adrenoreceptors, due to which peripheral resistance is reduced. In addition, Ebrantil regulates the central mechanism of maintaining vascular tone and has a weak beta-adrenoblocking effect.

The heart rate (HR) and cardiac output do not change with its administration. Low cardiac output may increase due to decreased vascular resistance. As a rule, Ebrantil does not cause orthostatic phenomena. Ebrantil blocks vasoconstriction caused by alpha-2-adrenoreceptors and does not cause reflex tachycardia due to vasodilatation.

Ebrantil reduces systolic and diastolic blood pressure (BP) in a balanced manner by reducing peripheral resistance and does not cause reflex tachycardia.

Urapidil reduces pre- and post-load on the heart and increases the efficiency of the heart contraction, thus, in the absence of arrhythmia, the drug increases the reduced cardiac minute volume.

Indications

Hypertensive crisis and severe, refractory arterial hypertension.

Pharmacological effect

Ebrantil is a drug that blocks postsynaptic alpha-1 adrenergic receptors, thereby reducing peripheral resistance. In addition, Ebrantil regulates the central mechanism for maintaining vascular tone and has a weak beta-blocking effect.

Heart rate (HR) and cardiac output do not change when administered. Low cardiac output may be increased by decreased vascular resistance. As a rule, Ebrantil does not cause orthostatic phenomena. Ebrantil blocks vasoconstriction caused by alpha-2 adrenergic receptors and does not cause reflex tachycardia caused by vasodilation.

Ebrantil balancedly reduces systolic and diastolic blood pressure (BP), reducing peripheral resistance and does not cause reflex tachycardia.

Urapidil reduces pre- and afterload on the heart, increases the efficiency of cardiac contraction, thereby, in the absence of arrhythmia, the drug increases the reduced cardiac output.

Special instructions

Use in pediatrics There are no clinical data on the use of the drug in children under 18 years of age.

Active ingredient

Urapidil

Composition

1 ml. contains urapidil hydrochloride 5.47 mg (corresponding to 5.0 mg urapidil),

Excipients:

propylene glycol;

sodium hydrogen phosphate dihydrate;

sodium dihydrogen phosphate dihydrate;

water for injections

Pregnancy

Contraindicated.

Contraindications

With caution: elderly age, impaired liver and/or kidney function, hypovolemia.

Side Effects

Most PEs are caused by a sharp decrease in blood pressure.

Frequency: very often – more than 1/10; often – more than 1/100 and less than 1/10; uncommon – more than 1/1000 and less than 1/100; rarely – more than 1/10000 and less than 1/1000; very rarely – less than 1/10000, incl. separate messages.

From the cardiovascular system: infrequently – palpitations, tachycardia, bradycardia, a feeling of compression behind the sternum, shortness of breath, arrhythmias.

From the digestive system: often – nausea, infrequently – vomiting.

From the side of the central nervous system: often – dizziness, headache, fatigue; very rarely – anxiety.

From the skin: infrequently – increased sweating.

Allergic reactions: rarely – itching, redness of the skin, exanthema.

From the genitourinary system: often – proteinuria; rarely – nephropathy, nephrotic syndrome; rarely – priapism.

Laboratory indicators: very rarely – thrombocytopenia.

Interaction

The hypotensive effect of urapidil may be enhanced when taken together with alpha-blockers or other antihypertensive drugs, as well as during hypovolemia (nausea, vomiting) and when taking ethanol.

When taking cimetidine simultaneously, the maximum concentration of urapidil in the blood plasma may increase by 15%.

Overdose

Symptoms: dizziness, orthostatic collapse, fatigue, lethargy.

Treatment: if there is a sharp drop in blood pressure, it is necessary to elevate the patient’s legs and begin infusion therapy to increase the volume of circulating blood. If these measures are ineffective, you can start infusion of vasoconstrictors under blood pressure control. In very rare cases, intravenous administration of catecholamines (0.5 – 1.0 mg of epinephrine (adrenaline) diluted in 10 ml of saline) is necessary.

Storage conditions

Store at a temperature not exceeding 30°C. Keep out of the reach of children.

Shelf life

2 years

Manufacturer

Takeda Austria GmbH, Austria